Loading...
01/10 17:27
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: modest revenue growth and strong SUBLOCADE performance are offset by execution risks and vague guidance. The Q&A reveals management's strategic focus but lacks specific targets, leading to uncertainty. The stock's market cap suggests modest volatility, aligning with a neutral prediction.
Total net revenue $302 million, increased 1% year-over-year. Record SUBLOCADE net revenue offset expected pricing pressure on SUBOXONE Film and the continued wind down of PERSERIS.
SUBLOCADE net revenue $209 million, increased 9% year-over-year. Sequentially increased 19%, driven by a 9% increase in dispense volume, stocking, and favorable gross-to-net dynamics.
SUBOXONE Film net revenue Benefited from favorable gross-to-net dynamics of $10 million. Outperformed expectations due to price stability in the U.S. and a modestly higher-than-expected market share of 14%.
Non-GAAP operating expenses $167 million, up 2% year-over-year. Selling and marketing expenses increased due to U.S. SUBLOCADE marketing, while G&A expenses decreased by 7%.
R&D expenses $21 million, decreased 20% year-over-year. Decrease due to reprioritization of pipeline activities and related cost savings.
Adjusted EBITDA $88 million, slightly down year-over-year. Modestly higher net revenue offset by increased marketing for U.S. SUBLOCADE.
Gross cash and investments $538 million, up from $347 million at year-end. Increase benefited by approximately $120 million from the timing of Medicaid rebate invoices, expected to unwind in Q3.
SUBLOCADE: Record net revenue of $209 million in Q2 2025, a 9% increase year-over-year. SUBLOCADE is the first and #1 prescribed LAI treatment for OUD, taken by over 350,000 people. Market share in the U.S. remained stable at approximately 75%.
SUBOXONE Film: Outperformed expectations due to price stability in the U.S. and a modestly higher-than-expected market share of 14%. Net revenue benefited from favorable gross-to-net dynamics of $10 million.
U.S. Market: Focus on improving commercial execution for SUBLOCADE and increasing penetration in the commercial channel, which currently represents only 25% of total patient volume.
London Stock Exchange Delisting: Indivior canceled its secondary listing on the London Stock Exchange to reduce costs and complexity, aligning with its increased U.S. focus.
Indivior Action Agenda: A 3-phase operational roadmap to maximize business potential. Phase 1 (2025) focuses on simplifying the organization, eliminating nonessential activities, and improving U.S. commercial execution. Phase 2 (2026) aims to accelerate SUBLOCADE growth and profitability. Phase 3 (2026 onwards) targets commercial stage acquisitions for growth.
Financial Guidance: Raised 2025 net revenue guidance to $1.030 billion-$1.080 billion and adjusted EBITDA guidance to $275 million-$300 million, reflecting a 20% increase at the midpoint.
Leadership Changes: Strengthened leadership team with new appointments, including a Chief Commercial Officer and EVP of Corporate Affairs, to drive the Indivior Action Agenda.
Focus on U.S. Operations: Shifted focus to U.S. operations, including delisting from the London Stock Exchange and joining the U.S. Russell Indexes.
U.S. Commercial Execution: The company acknowledges that U.S. commercial execution needs improvement, which is critical for driving growth and achieving strategic objectives.
Cost Structure and Complexity: The operations are described as complex with nonessential activities inflating costs and adversely impacting execution. Simplification is necessary to reduce costs and improve focus.
Specialty Pharmacy Channel Performance: Dispense yield rates within the commercial channel are trailing national averages, indicating inefficiencies in the distribution network that need to be addressed.
Pricing Pressure on SUBOXONE Film: The company anticipates pricing pressure on SUBOXONE Film in the second half of 2025, which could impact revenue.
Regulatory and Market Access Challenges: Efforts to improve healthcare provider awareness and payer coverage for updated SUBLOCADE dosing approaches highlight potential challenges in regulatory and market access.
Dependence on Single Product and Market: The business is heavily reliant on SUBLOCADE and the U.S. market, which poses risks if market conditions or product performance falter.
Transition Year Risks: 2025 is described as a transition year with significant organizational changes, which could introduce execution risks and uncertainties.
Supply Chain and Distribution Model: The need to improve the efficiency of the distribution model to ensure timely delivery of treatments to patients is highlighted as a challenge.
2025 Financial Guidance: The company has raised its total net revenue guidance for 2025 to a range of $1.030 billion to $1.080 billion, reflecting strong performance of SUBLOCADE and stable pricing for SUBOXONE Film in the U.S. Full-year SUBLOCADE net revenue guidance has been increased to $765 million to $785 million, representing 3% year-over-year growth at the midpoint. Adjusted EBITDA guidance has been raised to $275 million to $300 million, a 20% increase at the midpoint compared to previous expectations. The effective corporate tax rate for 2025 is expected to be between 19% and 22%.
SUBLOCADE Growth Strategy: The company is focused on improving commercial execution for SUBLOCADE in the U.S. during the second half of 2025 to generate momentum for 2026. Key initiatives include sharpening field force messaging, increasing healthcare provider awareness of updated SUBLOCADE labels, and improving distribution network performance. The company aims to accelerate SUBLOCADE growth in 2026 and beyond, with a focus on increasing profitability and cash flow generation at a rate exceeding revenue growth.
Indivior Action Agenda: The company has introduced a three-phase operational roadmap. Phase 1 (2025) focuses on generating momentum by simplifying the organization, eliminating nonessential activities, and improving U.S. commercial execution. Phase 2 (2026) aims to accelerate SUBLOCADE growth and profitability. Phase 3 (late 2026) will focus on leveraging financial strength for commercial-stage acquisitions to drive future growth.
The selected topic was not discussed during the call.
The company has raised its financial guidance for 2025, indicating strong performance and growth expectations. The Q&A section reveals effective cost management and strategic focus on SUBLOCADE's growth, with positive indicators such as increased dispense growth and prescriber base. Despite some management evasiveness, the overall sentiment is positive, supported by strong financial metrics and optimistic guidance.
The earnings call presents a mixed picture: modest revenue growth and strong SUBLOCADE performance are offset by execution risks and vague guidance. The Q&A reveals management's strategic focus but lacks specific targets, leading to uncertainty. The stock's market cap suggests modest volatility, aligning with a neutral prediction.
The earnings call indicates strong financial performance with significant revenue and net income growth. Despite some concerns such as pipeline risks and gross margin decline, the positive aspects like the successful share buyback program, strong cash position, and optimistic guidance for SUBLOCADE overshadow them. The Q&A further supports a positive outlook with encouraging data on new patient share and strategic focus on SUBLOCADE. Given the market cap, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
